64th ASH Annual Meeting and Exposition: 902. Health Services and Quality—Lymphoid Malignancies: Real World Consequences and Cost of Care

Symposia: Health Services and Quality—Lymphoid Malignancies Oral and Poster Abstracts
Oral

Research, Biological therapies, Lymphoid Leukemias, adult, Clinical Practice (Health Services and Quality), Lymphomas, CLL, non-Hodgkin lymphoma, epidemiology, elderly, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, Clinical Research, health outcomes research, health disparities research, Diseases, drug-drug interactions, Therapies, therapy sequence, real-world evidence, Adverse Events, Lymphoid Malignancies, Study Population, Human, Transplantation

La Nouvelle Orleans Ballroom AB (Ernest N. Morial Convention Center)

Moderators:

Ja Min Byun, MD, PhD, Seoul National University Hospital and Urshila Durani, MD, MPH, Mayo Clinic

Disclosures:

No relevant conflicts of interest to declare.

Moderators: Urshila Durani, Ja Min Byun

Back-up: Carla Casulo

2:45 PM

889

Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Neda Alrawashdh, PharmD¹^*, Ali McBride^2,3 and Ivo Abraham, PhD, RN⁴

¹Center for Health Outcomes and Pharmacoeconomic Research, university of arizona, TUCSON, AZ
²Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, NJ
³Bristol Myers Squibb, Princeton, NJ
⁴Center for Health Outcomes and PharmacoEconomic Research, University of Arizona - College of Pharmacy, Tucson, AZ

3:00 PM

890

The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab

Kimberly Guinan, MSc¹^*, Jean Lachaine, PhD^1,2^*, Nancy Paul Roc, MSc³^*, Sarah-Jane Bull, PhD⁴^*, Dipti Tankala, PharmD, MPharm, MBA³^*, Stéphane Barakat, PhD³^*, Christopher M. Hillis, MD⁵ and Versha Banerji, MD^6,7

¹PeriPharm Inc., Montreal, QC, Canada
²Faculty of pharmacy, Université de Montréal, Montreal, QC, Canada
³AbbVie Corporation, Saint-Laurent, QC, Canada
⁴Medical Affairs, AbbVie Corporation, Saint-Laurent, QC, Canada
⁵Faculty of Medicine, McMaster University, Hamilton, ON, Canada
⁶CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada
⁷Departments of Internal Medicine and Biochemistry & Medical Genetics, Rady Faculty of Health Sciences, Winnipeg, MB, Canada

3:15 PM

891

The Impact of Drug Interactions on Outcomes in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia in Routine Clinical Care: A Population-Based Cohort Study

Tuan Hoang, MD, PhD¹^*, Matthew C. Cheung, MD, MSc^1,2,3,4, Kelvin KW Chan, MD, MSc, PhD^1,2,3,4^*, Cindy Lau, MPH²^*, Ning Liu, MSc, PhD²^*, Husam Abdel-Qadir, MD, PhD^1,5^*, David Juurlink, MD, PhD^1,2,4^*, Anca Prica, MD, MSc^1,6, Alia Thawer, PharmD³^*, Abi Vijenthira, MD^1,6 and Lee Mozessohn^1,2,4,7

¹Department of Medicine, University of Toronto, Toronto, ON, Canada
²ICES, Toronto, ON, Canada
³Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
⁴Sunnybrook Research Institute, Toronto, ON, Canada
⁵Peter Munk Cardiac Center, University Health Network, Toronto, ON, Canada
⁶Princess Margaret Cancer Centre, Toronto, ON, Canada
⁷Division of Hematology/Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

3:30 PM

892

Hospital Costs and Healthcare Resource Utilization (HRU) for Chimeric Antigen (CAR) T-Cell Therapy and Stem Cell Transplant (SCT) in Patients with Large B-Cell Lymphoma (LBCL) in the United States (US)

Chendi Cui¹^*, Chaoling Feng, PhD²^*, Ning Rosenthal, MD, MPH, PhD³^*, Sally W Wade, MPH⁴^*, Laura Curry, MS, PhD³^*, Christine Fu, PhD⁵^* and Gunjan L. Shah, MD⁶

¹PINC AI Applied Sciences, Premier Inc., Wexford, PA
²Kite, A Gilead Company, Santa Monica, CA
³PINC AI Applied Sciences, Premier Inc., Charlotte, NC
⁴Wade Outcomes Research and Consulting, Salt Lake City, UT
⁵Kite, a Gilead Company, Santa Monica, CA
⁶Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

3:45 PM

893

Cost-Utility of Venetoclax Plus Obinutuzumab for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia without Del17p/TP53-Mutation Compared to Chlorambucil Plus Obinutuzumab

Matilde Slot, MSc^1,2^*, Carsten Utoft Niemann, MD, PhD³, Bettina Wulff Risør, PhD^1,2^*, Lars Holger Ehlers, PhD¹^* and Emelie Rotbain, MD^3,4^*

¹Nordic Institute of Health Economics, Aarhus, Denmark
²Department of Clinical Medicine, Aalborg University, Aalborg Ø, Denmark
³Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
⁴Danish Cancer Society Research Center, Copenhagen, DNK

4:00 PM

894

Phase-Specific Costs of Care in Hematological Malignancies in Ontario, Canada

Judy Truong, MD¹, Soo Jin Seung²^*, Christoffer Dharma³^*, Stephanie Y Cheng⁴^*, Craig Earle, MD, FASCO³^*, Simron Singh, MD, MPH^5,6^*, Nicole Mittman, PhD⁴^* and Matthew C. Cheung, MD, MSc⁶

¹University of Toronto, North York, ON, Canada
²Sunnybrook Research Institute, Toronto, Canada
³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
⁴Institute for Clinical Evaluative Sciences, Toronto, Canada
⁵ICES, Toronto, ON, Canada
⁶Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902.O1.6 902. Health Services and Quality—Lymphoid Malignancies: Real World Consequences and Cost of Care